| 发明名称 | Eye drops | ||
| 摘要 | An eyedrop containing a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmacologically acceptable salt thereof; and a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (“FGLM”), or a pharmacologically acceptable salt thereof. The concentration ratio between SSSR or a pharmacologically acceptable salt thereof and FGLM or a pharmacologically acceptable salt thereof is between 1/15 and 1/50. The concentration of SSSR or a pharmacologically acceptable salt thereof is between 0.001% and 0.3% (w/v) and the concentration of FGLM or a pharmacologically acceptable salt thereof is between 0.015% and 1.5% (w/V). The pH of the eye drop is maintained between 2.5 and 6.5. | ||
| 申请公布号 | US8865654(B2) | 申请公布日期 | 2014.10.21 |
| 申请号 | US201013394194 | 申请日期 | 2010.09.24 |
| 申请人 | Santen Pharmaceutical Co., Ltd. | 发明人 | Nakamura Takahiro;Nakada Yuichiro;Nagano Takashi;Nakamura Masatsugu |
| 分类号 | A61K38/00;A61P9/10;A61P27/02;A61K38/07;A61K9/00;C07K5/107;C07K5/103 | 主分类号 | A61K38/00 |
| 代理机构 | Holtz, Holtz, Goodman & Chick, PC | 代理人 | Holtz, Holtz, Goodman & Chick, PC |
| 主权项 | 1. An eye drop comprising (i) an acetate of a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg and (ii) a hydrochloride of a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2, wherein (a) a concentration ratio of the acetate of a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg to the hydrochloride of a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 is 1/15 to 1/50; (b) the acetate of a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg has a concentration of 0.001 to 0.3% (w/v); (c) the hydrochloride of a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 has a concentration of 0.015 to 1.5% (w/v); and (d) the eye drop has a pH of 2.5 to 6.5. | ||
| 地址 | Osaka-shi, Osaka JP | ||